News | Brachytherapy Systems | January 02, 2018

California US Oncology Network Centers Adopt Xoft Electronic Brachytherapy System for Early-Stage Non-Melanoma Skin Cancer

Prominent cancer centers expand portfolio of patient-centric treatment solutions with Xoft’s painless, scar-free solution

California US Oncology Network Centers Adopt Xoft Electronic Brachytherapy System for Early-Stage Non-Melanoma Skin Cancer

January 2, 2018 — iCAD Inc. announced that its Xoft Axxent Electronic Brachytherapy (eBx) System is now available at two California-based centers from The US Oncology Network – Santa Clarita Radiation Therapy Center and Sherman Oaks Radiation Therapy Center. Local patients with non-melanoma skin cancer (NMSC), including individuals precluded from surgery or those seeking a non-invasive option, will now have access to a proven alternative.

“We are pleased to provide our community with the most advanced and targeted cancer care that meets the needs of each and every patient,” said May Lin Tao, M.D., medical director of Santa Clarita Radiation Therapy Center.

“Adding Xoft to our infrastructure expands our clinical tools, which help patients achieve similar low rates of recurrence with excellent cosmetic outcomes compared to Mohs surgery – all with virtually no downtime,” said Marc Botnick, M.D., medical director of Sherman Oaks Radiation Therapy Center.

The Xoft technology features a miniaturized, low-energy X-ray source that delivers a precise dose of targeted, isotope-free radiation therapy directly to the lesion, reducing the risk of damage to surrounding healthy tissue. The mobile system can be easily maneuvered from room to room, while minimal shielding requirements enable clinicians to deliver treatment in a standard exam room, offering a highly-efficient, flexible solution.

Appropriate candidates include NMSC patients with lesions in anatomically challenging locations such as the ears, nose, scalp, neck, shin, and elbows, as well as those with wound healing challenges, individuals taking anticoagulants, and patients with medical comorbidities that may prohibit them from surgery.

The Xoft System is cleared by the U.S. Food and Drug Administration (FDA), CE marked and licensed in a growing number of countries for the treatment of cancer anywhere in the body, including NMSC, early-stage breast cancer and gynecological cancers.

For more information: www.icadmed.com

Related Content

Videos | Radiation Therapy | February 20, 2019
ITN Associate Editor Jeff Zagoudis speaks with Vinai Gondi, M.D., director of research and CNS neuro-oncology at the
Study Unveils Blueprint for Treating Radiation-Resistant Brain Tumor

NIH-funded researchers showed how gliomas may be treated with radiation and drugs that block DNA repair. Image courtesy of Castro lab, Michigan Medicine, Ann Arbor

 

News | Radiation Therapy | February 19, 2019
February 19, 2019 — Researchers at the University of Michigan recently searched for new brain tumor treatments by exp
Videos | Radiation Therapy | February 15, 2019
ITN Associate Editor Jeff Zagoudis speaks with Vinai Gondi, M.D., director of research and CNS neuro-oncology at the
New Targeted Therapy for Recurrent Brain Tumors Implanted for First Time
News | Radiation Therapy | February 15, 2019
University of Minnesota Health (M Health) is the first in the United States to begin offering GammaTile Therapy, a new...
Canon Adds Radiation Therapy Package to Aquilion Prime, Lightning CT Systems
News | Computed Tomography (CT) | February 11, 2019
In the patient-centric world of radiation oncology, it is critical that computed tomography (CT) simulation is...
Elekta Unity MR-Linac Earns FDA Clearance
Technology | Image Guided Radiation Therapy (IGRT) | February 07, 2019
The Elekta Unity magnetic resonance radiation therapy (MR/RT) system recently received 510(k) premarket notification...
University of Oklahoma Cancer Center Begins First Proton Therapy Treatments
News | Proton Therapy | February 01, 2019
Home to the largest and most comprehensive radiation therapy program in Oklahoma, the Stephenson Cancer Center at OU (...
Stereotactic Radiotherapy Improves Long-Term Survival in Stage-IV Cancers
News | Stereotactic Body Radiation Therapy (SBRT) | January 31, 2019
The first report from a phase II, multi-center clinical trial indicates stereotactic radiation can extend long-term...
Philips Collaborates With MIM Software on Radiation Therapy Treatment Planning
News | Treatment Planning | January 31, 2019
January 31, 2019 — Philips announced a collaboration with imaging solutions provider MIM Software Inc.
Videos | Lung Cancer | January 29, 2019
Gregory Videtic, M.D., staff physician in radiation oncology at the Cleveland Clinic, and David Johnstone, M.D., prof